Loading company…
Sightera Biosciences uses AI to discover small-molecule drug candidates for oncology and fibrotic diseases.
Sightera Biosciences uses AI and patient-derived tissue data to design small molecules for oncology and fibrotic diseases. Its research includes potential therapies for several cancers, including KRAS mutant pancreatic, biliary tract, and colorectal cancers. Based in Antwerp, Belgium, it raised EUR 3 million in pre-seed funding in July 2026 from Qbic Fund, Anacura, and Entourage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in